| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
41,560,000 |
| Market
Cap: |
248.53(M) |
| Last
Volume: |
5,200 |
Avg
Vol: |
5,186 |
| 52
Week Range: |
$3.61 - $10.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Appliances & Equipment |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Axogen is focused on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Co.'s platform for peripheral nerve repair features a portfolio of products, including Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; and Axoguard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Co. also provides Axotouch Two-Point Discriminator, which is used to measure the innervation density of any surface area of the skin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
30,000 |
30,000 |
| Total Buy Value |
$0 |
$0 |
$188,940 |
$188,940 |
| Total People Bought |
0 |
0 |
3 |
3 |
| Total Buy Transactions |
0 |
0 |
3 |
3 |
| Total Shares Sold |
118,082 |
130,582 |
180,030 |
368,410 |
| Total Sell Value |
$980,899 |
$1,074,708 |
$1,509,387 |
$3,484,755 |
| Total People Sold |
5 |
6 |
6 |
6 |
| Total Sell Transactions |
6 |
7 |
9 |
21 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Scopelianos Angelo |
Chief R&D Officer |
• – – |
2021-02-17 |
4 |
D |
$18.71 |
$7,596 |
D/D |
(406) |
7,046 |
|
- |
|
| Devinney Erick Wayne |
VP, Clinical&Translational Sc |
• – – |
2021-02-17 |
4 |
D |
$18.70 |
$34,857 |
D/D |
(1,864) |
68,082 |
|
- |
|
| Sandberg Eric |
Chief Commercial Officer |
• – – |
2021-02-17 |
4 |
D |
$18.70 |
$16,886 |
D/D |
(903) |
3,223 |
|
- |
|
| Billet Isabelle |
Chief Strategy and BD Officer |
• – – |
2021-02-17 |
4 |
D |
$18.71 |
$8,494 |
D/D |
(454) |
11,080 |
|
- |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
2,605 |
42,854 |
|
- |
|
| Freitag Gregory Gene |
Director |
– • – |
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
5,161 |
252,897 |
|
- |
|
| Mariani Peter J |
Chief Financial Officer |
• – – |
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
10,812 |
19,023 |
|
- |
|
| Zaderej Karen L. |
CEO |
• • – |
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
29,999 |
634,916 |
|
- |
|
| Friedman Mark Louis |
VP, Regulatory & Quality |
• – – |
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
3,111 |
14,297 |
|
- |
|
| Martinez Maria D. |
Chief Human Resources Officer |
• – – |
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,325 |
5,990 |
|
- |
|
| Scopelianos Angelo |
Chief R&D Officer |
• – – |
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,325 |
7,452 |
|
- |
|
| Devinney Erick Wayne |
VP, Clinical&Translational Sc |
• – – |
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
6,231 |
68,404 |
|
- |
|
| Sandberg Eric |
Chief Commercial Officer |
• – – |
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
2,531 |
4,126 |
|
- |
|
| Billet Isabelle |
Chief Strategy and BD Officer |
• – – |
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,325 |
11,534 |
|
- |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2021-02-05 |
4 |
D |
$19.81 |
$102,814 |
D/D |
(5,190) |
40,839 |
|
- |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2021-02-05 |
4 |
OE |
$5.14 |
$102,800 |
D/D |
20,000 |
46,029 |
|
- |
|
| Zaderej Karen L. |
CEO |
• • – |
2021-01-08 |
4 |
AS |
$20.00 |
$1,300,000 |
D/D |
(65,000) |
609,099 |
|
7% |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2020-12-30 |
4 |
AS |
$17.48 |
$30,293 |
D/D |
(1,733) |
26,029 |
|
21% |
|
| Mariani Peter J |
Chief Financial Officer |
• – – |
2020-12-29 |
4 |
S |
$17.81 |
$23,028 |
D/D |
(1,293) |
10,376 |
|
-25% |
|
| Billet Isabelle |
Chief Strategy and BD Officer |
• – – |
2020-12-29 |
4 |
S |
$17.81 |
$11,559 |
D/D |
(649) |
9,496 |
|
-25% |
|
| Martinez Maria D. |
Chief Human Resources Officer |
• – – |
2020-12-29 |
4 |
S |
$17.81 |
$10,098 |
D/D |
(567) |
4,665 |
|
-25% |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2020-12-29 |
4 |
S |
$17.81 |
$10,098 |
D/D |
(567) |
27,762 |
|
-25% |
|
| Zaderej Karen L. |
CEO |
• • – |
2020-12-29 |
4 |
S |
$17.81 |
$62,335 |
D/D |
(3,500) |
674,099 |
|
-25% |
|
| Friedman Mark Louis |
VP,Regulatory & Quality |
• – – |
2020-12-29 |
4 |
S |
$17.81 |
$10,098 |
D/D |
(567) |
11,124 |
|
-25% |
|
| Scopelianos Angelo |
VP Research & Development |
• – – |
2020-12-29 |
4 |
S |
$17.81 |
$10,098 |
D/D |
(567) |
5,529 |
|
-25% |
|
470 Records found
|
|
Page 10 of 19 |
|
|
0.11 (1.87%) 
